BetterLife Pharma Secures Patent for BETR-001, Strengthening Biotech Position

BetterLife Pharma ( (TSE:BETR) ) has provided an announcement.

BetterLife Pharma has announced that the United States Patent and Trademark Office has issued an Issue Notification for the composition of matter patent for BETR-001, providing robust intellectual property protection until at least 2042. This patent strengthens BetterLife’s position in the biotech industry as it prepares for the IND filing and human trials of BETR-001 in 2026, potentially impacting the treatment of psychiatric and neurological disorders.

Spark’s Take on TSE:BETR Stock

According to Spark, TipRanks’ AI Analyst, TSE:BETR is a Underperform.

BetterLife Pharma is currently in a precarious financial position with no revenue, substantial losses, and a high leverage risk due to negative equity. Technical indicators show a lack of momentum, and the valuation is unattractive due to negative earnings. The overall outlook is negative, reflecting significant financial instability.

To see Spark’s full report on TSE:BETR stock, click here.

More about BetterLife Pharma

BetterLife Pharma Inc. is an emerging biotechnology company focused on developing and commercializing compounds for the treatment of neuro-psychiatric and neurological disorders. Their primary products include BETR-001, a non-hallucinogenic neuroplastogen, and BETR-002, based on honokiol for anxiety-related disorders. The company is also exploring strategic alternatives for a drug candidate aimed at treating viral infections.

Average Trading Volume: 47,721

Technical Sentiment Signal: Sell

Current Market Cap: C$13.09M

See more data about BETR stock on TipRanks’ Stock Analysis page.